|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
13
|
|
pubmed:dateCreated |
2008-6-16
|
|
pubmed:abstractText |
The preparation and evaluation of a novel class of CB2 agonists based on a benzimidazole moiety are reported. They showed binding affinities up to 1nM towards the CB2 receptor with partial to full agonist potencies. They also demonstrated good to excellent selectivity (>1000-fold) over the CB1 receptor.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Benzimidazoles,
http://linkedlifedata.com/resource/pubmed/chemical/Cannabinoids,
http://linkedlifedata.com/resource/pubmed/chemical/Endocannabinoids,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, Cannabinoid, CB1,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, Cannabinoid, CB2,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Cannabinoid,
http://linkedlifedata.com/resource/pubmed/chemical/benzimidazole
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
1464-3405
|
|
pubmed:author |
pubmed-author:BalauxEliseE,
pubmed-author:BoisvertLucL,
pubmed-author:BrownWilliamW,
pubmed-author:ChengYun-XingYX,
pubmed-author:FeiZhouZ,
pubmed-author:GodboutClaudeC,
pubmed-author:HodzicLeilaL,
pubmed-author:LiuZipingZ,
pubmed-author:LuoXuehongX,
pubmed-author:MilburnClaireC,
pubmed-author:PagéDanielD,
pubmed-author:PayzaKemalK,
pubmed-author:PayzaKeymalK,
pubmed-author:SaloisDominicD,
pubmed-author:SrivastavaSanjayS,
pubmed-author:St-OngeStéphaneS,
pubmed-author:TomaszewskiMiroslawM,
pubmed-author:TremblayMaximeM,
pubmed-author:WalpoleChristopherC,
pubmed-author:WeiZhongyongZ,
pubmed-author:WooSimonS,
pubmed-author:YangHuaH
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
18
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3695-700
|
|
pubmed:dateRevised |
2008-10-25
|
|
pubmed:meshHeading |
pubmed-meshheading:18522867-Benzimidazoles,
pubmed-meshheading:18522867-Binding, Competitive,
pubmed-meshheading:18522867-Cannabinoids,
pubmed-meshheading:18522867-Chemistry, Pharmaceutical,
pubmed-meshheading:18522867-Drug Design,
pubmed-meshheading:18522867-Endocannabinoids,
pubmed-meshheading:18522867-Humans,
pubmed-meshheading:18522867-Models, Chemical,
pubmed-meshheading:18522867-Receptor, Cannabinoid, CB1,
pubmed-meshheading:18522867-Receptor, Cannabinoid, CB2,
pubmed-meshheading:18522867-Receptors, Cannabinoid,
pubmed-meshheading:18522867-Structure-Activity Relationship,
pubmed-meshheading:18522867-Technology, Pharmaceutical
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Novel benzimidazole derivatives as selective CB2 agonists.
|
|
pubmed:affiliation |
Department of Medicinal Chemistry, AstraZeneca R&D Montréal, 7171 Frederick-Banting, St-Laurent, Que., Canada. daniel.page@astrazeneca.com
|
|
pubmed:publicationType |
Journal Article
|
